Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Context: Both type 2 diabetes (T2D) and osteoporosis are affected by aging and quite often coexist. Furthermore, the fracture risk in patients with T2D is increased. The aim of this article is to review updated information on osteoporosis and fracture risk in patients with T2D, to discuss the effects of diabetes treatment on bone metabolism, as well as the effect of antiosteoporotic medications on the incidence and control of T2D, and to provide a personalized guide to the optimal management. Evidence Acquisition: A systematic literature search for human studies was conducted in three electronic databases (PubMed, Cochrane, and EMBASE) until March 2017. Regarding recommendations, we adopted the grading system introduced by the American College of Physicians. Evidence Synthesis: The results are presented in systematic tables. Healthy diet and physical exercise are very important for the prevention and treatment of both entities. Metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 receptor agonists should be preferred for the treatment of T2D in these patients, whereas strict targets should be avoided for the fear of hypoglycemia, falls, and fractures. Insulin should be used with caution and with careful measures to avoid hypoglycemia. Thiazolidinediones and canagliflozin should be avoided, whereas other sodium-dependent glucose transporter 2 inhibitors are less well-validated options. Insulin therapy is the preferred method for achieving glycemic control in hospitalized patients with T2D and fractures. The treatment and monitoring of osteoporosis should be continued without important amendments because of the presence of T2D. Conclusions: Patients with coexisting T2D and osteoporosis should be managed in an optimal way according to scientific evidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 3×
“otherapy if metformin is contraindicated or not well tolerated) (111), sulfonylureas, DPP-4i, or GLP-1RA”
BackgroundInfluentialGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“There are three levels of “strength ” (s rong, weak, insufficient) and three levels of “quality” (high, moderate, low) [4].”
BackgroundMechanisms of diabetes mellitus-induced bone fragility
On behalf of the IOF Bone and Diabetes Working Group, Napoli, N., Chandran, M., Pierroz, D. D., Abrahamsen, B., Schwartz, A. V., & Ferrari, S. L. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.153 · Cited by 1,107
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652 · cited 5×
“Of the followi ng six treatment options, sulfonylureas, TZDs, DPP-4i, SGLT2i, GLP1-RA or basal insulin, tha t represent the current general second line treatment on patients with T2D (presenting als o a options for monotherapy if metformin is contraindicated or not well tolerated) [114], su lfonylureas, DPP-4i or GLP1…”
BackgroundResultInfluentialEffects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus
Watts, N. B., Bilezikian, J. P., Usiskin, K., Edwards, R., Desai, M., Law, G., & Meininger, G. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3167 · Cited by 454
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253 · cited 13×
“Experimental studies have indicatedbeneficial effects on bone formation (69), whereas large clinical studies resulted in neutral or positive effects on BMD and fracture risk, in different and various large patient cohorts (5, 20–29).”
BackgroundInfluentialMa, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200 · cited 4×
“If the addition of a third agent is needed, this should be decided again in th e same context [22-78, 114-116].”
BackgroundInfluentialIepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193 · cited 4×
“If the addition of a third agent is needed, this should be decided again in th e same context [22-78, 114-116].”
BackgroundInfluentialMabilleau, G., Mieczkowska, A., & Chappard, D. (2014) · Journal of Diabetes · doi:10.1111/1753-0407.12102 · Cited by 178
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166 · cited 2×
“Bays HE, 2014 (61) 376 (cana) 12 wk ↔ ↑ Bolinder J, 2014 (62) 182 (dapa) 102 wk ↔ ↔ ↔ ↔ Kohan DE, 2014 (63) 252 (dapa) 104 wk ↑ Ptaszynska A, 2014 (64) 3281 (dapa, 12 studies) Pool analysis ↔ Ljunggren O, 2012 (65) 165 (dapa) 50 wk ↔ ↔ ↔ ↔ Insulin Napoli N, 2014 (MrOS) (20) 881 T2D / 5994 total (M) 9.”
3. Foundations of Care and Comprehensive Medical Evaluation
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s006 · Cited by 159
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85 · cited 17×
“Of the followi ng six treatment options, sulfonylureas, TZDs, DPP-4i, SGLT2i, GLP1-RA or basal insulin, tha t represent the current general second line treatment on patients with T2D (presenting als o a options for monotherapy if metformin is contraindicated or not well tolerated) [114], su lfonylureas, DPP-4i or GLP1…”
BackgroundInfluentialBone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Carr, M. C., Knopp, R. H., Brunzell, J. D., Wheeler, B. S., Zhu, X., Lakshmanan, M., Rosen, A. S., & Anderson, P. W. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1555 · Cited by 22
Cited by
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Gadelha, M. R., Kasuki, L., Lim, D. S. T., & Fleseriu, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00115 · Cited by 363
Effects of anti-diabetic drugs on fracture risk: a systematic review and network meta-analysis
Zhang, Y.-S., Zheng, Y.-D., Yuan, Y., Chen, S.-C., & Xie, B.-C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.735824 · Cited by 117
The impact of type 2 diabetes on bone metabolism
Sanches, C. P., Vianna, A. G. D., & Barreto, F. D. C. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0278-1 · Cited by 115
Cai, T.-T., Li, H.-Q., Jiang, L.-L., Wang, H.-Y., Luo, M.-H., Su, X.-F., & Ma, J.-H. (2021) · BioMed Research International · doi:10.1155/2021/3361309 · Cited by 84
Identification of a prolonged action molecular GLP-1R agonist for the treatment of femoral defects
Wang, N., Liu, X., Shi, L., Liu, Y., Guo, S., Liu, W., Li, X., Meng, J., Ma, X., & Guo, Z. (2020) · Biomaterials Science · doi:10.1039/c9bm01426h · Cited by 18
Metadata
- Authors
- Paschou, S. Α., Dede, A. D., Anagnostis, P. G., Vryonidou, A., Morganstein, D., & Goulis, D. G.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2017-06-21
- Volume
- 102
- Issue
- 10
- Pages
- 3621-3634
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2669395868
- Cited by
- 205
- References
- 15
- FWCI
- 13.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.